PMID- 37255963
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230601
IS  - 1179-1438 (Print)
IS  - 1179-1438 (Electronic)
IS  - 1179-1438 (Linking)
VI  - 15
DP  - 2023
TI  - Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose 
      Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes 
      Mellitus.
PG  - 41-55
LID - 10.2147/CPAA.S409786 [doi]
AB  - PURPOSE: In people with type 2 diabetes mellitus (T2DM), both glucose metabolism 
      abnormalities and atherosclerosis risk are significant concerns. This study aims 
      to investigate the effects of the sodium-glucose cotransporter 2 inhibitor 
      tofogliflozin (TOFO) and the dipeptidyl peptidase-4 inhibitor anagliptin (ANA) on 
      markers of glucose metabolism and atherosclerosis when administered individually 
      or in combination. METHODS: Fifty T2DM patients were divided into two groups 
      (receiving either TOFO or ANA monotherapy) and observed for 12 weeks (observation 
      points: 0 and 12 weeks). The TOFO and ANA groups were then further treated with 
      ANA and TOFO, respectively, and the patients were observed for an additional 36 
      weeks (observation points: 24 and 48 weeks). Therapeutic effects and various 
      biomarkers were compared between the two groups at the observation points. 
      RESULTS: Combination therapy led to significant improvements in HbA1c levels and 
      atherosclerosis markers. Additionally, the TOFO pretreatment group exhibited 
      significant reductions in sLOX-1 and IL-6 levels. CONCLUSION: The increase in 
      sLOX-1 and IL-6 levels, which indicates the response of scavenger receptors to 
      oxidized low-density lipoproteins in people with T2DM, is mitigated following 
      TOFO and ANA combination therapy. TOFO alone or in combination with ANA may be 
      beneficial for preventing atherosclerosis development in people with T2DM, in 
      addition to its effect on improving HbA1c levels.
CI  - (c) 2023 Nomura et al.
FAU - Nomura, Shosaku
AU  - Nomura S
AUID- ORCID: 0000-0002-6371-9472
AD  - Center of Thrombosis and Hemostasis, Kansai Medical University Medical Center, 
      Moriguchi, Japan.
FAU - Shouzu, Akira
AU  - Shouzu A
AD  - Division of Diabetes, Saiseikai Izuo Hospital, Osaka, Japan.
FAU - Taniura, Takehito
AU  - Taniura T
AD  - Division of Internal Medicine, Daiwa Hospital, Osaka, Japan.
FAU - Okuda, Yoshinori
AU  - Okuda Y
AUID- ORCID: 0009-0007-3635-5638
AD  - Division of Internal Medicine, Meisai Kinen Hospital, Osaka, Japan.
FAU - Omoto, Seitaro
AU  - Omoto S
AD  - Division of Internal Medicine, Yukeikai Hospital, Neyagawa, Japan.
FAU - Suzuki, Masahiko
AU  - Suzuki M
AD  - Division of Internal Medicine, Katano Hospital, Katano, Japan.
FAU - Ito, Tomoki
AU  - Ito T
AUID- ORCID: 0000-0001-5419-9156
AD  - First Department of Internal Medicine, Kansai Medical University, Hirakata, 
      Japan.
FAU - Toyoda, Nagaoki
AU  - Toyoda N
AD  - Second Department of Internal Medicine, Kansai Medical University, Hirakata, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20230525
PL  - New Zealand
TA  - Clin Pharmacol
JT  - Clinical pharmacology : advances and applications
JID - 101564865
PMC - PMC10226515
OTO - NOTNLM
OT  - anagliptin
OT  - atherosclerosis
OT  - soluble LOX-1
OT  - tofogliflozin
OT  - type 2 diabetes mellitus
COIS- The authors declare that they have no competing interests in this work.
EDAT- 2023/05/31 13:12
MHDA- 2023/05/31 13:13
PMCR- 2023/05/25
CRDT- 2023/05/31 10:32
PHST- 2023/03/14 00:00 [received]
PHST- 2023/05/19 00:00 [accepted]
PHST- 2023/05/31 13:13 [medline]
PHST- 2023/05/31 13:12 [pubmed]
PHST- 2023/05/31 10:32 [entrez]
PHST- 2023/05/25 00:00 [pmc-release]
AID - 409786 [pii]
AID - 10.2147/CPAA.S409786 [doi]
PST - epublish
SO  - Clin Pharmacol. 2023 May 25;15:41-55. doi: 10.2147/CPAA.S409786. eCollection 
      2023.